Inside informationEnglish
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Transgene S.A.
- Filed
- 24/03/2026, 17:45
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 111924_20260324